SBIR reform should be judged by one question: does it turn grants into a launchpad toward real markets and customers, or lock firms into permanent, grant-dependent life support?

Since we started this annual exercise in 2015, we have outperformed the market in nine of the 11 years. On average, the portfolio delivered an impressive return of 22.9% per year.

Dividend stocks (which commonly are value stocks, but can be growth stocks) are great ways to drive long-term performance of ...

Flowchart vs. process map, what do you choose to use? When it comes to mapping out a project, you’ve got several choices on how to visualize them. If you’ve had trouble deciding on a format for your ...

CAMARILLO, Calif., Dec. 2, 2025 /PRNewswire/ -- PBS Biotech ("PBS"), a leader in single-use bioreactor technology, today announced the launch of MiniPRO™, a multi-parallel Vertical-Wheel ® bioreactor ...

Insmed is rated a hold, reflecting a robust therapeutic pipeline but persistent unprofitability, and is priced at a high ...

Discover 10 undervalued healthcare stocks and why pharmaceuticals and providers stand out for value and quality.

If you are wondering whether Shell is still a smart buy after its big run over the last few years, or if most of the upside ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Hedge funds betting on drugs stocks have made bumper profits this year, as a recent wave of deals by big ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it, the ...

Good afternoon, and thank you for joining us as we discuss the fourth quarter and full year results for 2024 and our guidance for 2025 and our recently announced safe harbor transaction. Operationally ...

Krystal Biotech Inc. Annual cash flow by MarketWatch. View KRYS net cash flow, operating cash flow, operating expenses and cash dividends.